Organogenesis to merge to create $673M company: 4 notes

Written by Shayna Korol | August 27, 2018 | Print  |

Avista Healthcare Public Acquisition will merge with the regenerative medicine company Organogenesis.

Here are four things to know:

1. Organogenesis will become a wholly owned subsidiary of Avista.

2. Avista Capital Partners' affiliates agreed to invest $92 million in the combined company in conjunction with the transaction.

3. The combined company's anticipated initial enterprise value is approximately $673 million.

4. Organogenesis offers bioactive and acellular biomaterials products in advanced wound care, sports medicine and surgical biologics, including orthopedics and spine.

More articles on biologics:
6 things to know about Isto Biologics
Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know
Vericel appoints CMO: 3 details

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months